Biogen Advances Alzheimer’s Drug Diranersen to Phase 3 After It Slashes Tau and Slows Cognitive Decline

Biogen’s diranersen showed robust tau reduction and slowed cognitive decline in early Alzheimer’s Phase 2 trial. Moving to late-stage studies despite missing primary endpoint.